Also found in: Medical.
CD40Cluster of Differentiation 40 (glycoprotein)
References in periodicals archive ?
and the multidisciplinary cooperative research organisation Pediatric Brain Tumor Consortium (PBTC) have formed a clinical trial collaboration to evaluate Apexigen's APX005M, an investigational immune activating compound that targets CD40, in pediatric patients with recurrent or refractory brain tumors, the company said.
It also tried to find out possible correlation between the studied SNP in CD40 and CD28 genes with GD and also to determine the association of various studied epidemiological parameters with the studied disease, if any.
We are trying to understand if CD40 is capable of killing tumour cells that specifically originate from people who are younger.
Keywords: Hypercholesterolemia, atherosclerosis, CD40 ligand cok LDL-kolesterol, trigliserit, 8-OHdG, F1+2 arasinda anlamli korelasyon kurulamamistir (p>0,005).
Previous research has shown that drugs that activate immune cells by targeting CD40 proteins on their surface promote antitumor responses.
The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
APOA5 (b) Chr11 4 1101 False LDLRAP1 Chr1 9 927 False MMP9 Chr20 13 2124 False PDGFRB Chr5 23 3321 False VEGFA Chr6 7 1239 False ACTA2 Chr10 9 1134 True APOC3 Chr11 4 300 False CAV1 Chr7 3 537 False CD40 Chr20 9 834 False CETP Chr16 16 1482 False CIITA Chr16 20 3396 False FGG Chr4 10 1362 True GPX1 Chr3 1 612 True LPL Chr8 10 1428 False MBL2 Chr10 4 747 True MVK Chr12 11 1191 False PITX2 Chr4 6 954 False TNFRSF1A Chr12 10 1368 False UCP2 Chr11 8 930 False Gene name GC content APOA5 (b) 0.
The pathophysiological mechanisms underlying FSGS may be different from case to case, ranging from nonspecific podocyte injury to abnormal immune response (probably in our patient) with production of CLCF-1 or anti-CD40 antibodies and suPAR and up to podocyte expression of molecules including B7-1, B7-2, and CD40.
DC maturation is critical for inducing immune responses and can be characterized by cellular morphology and selected costimulatory molecule expression, such as that of CD86, CD83, CD80, CD40, and MHC I and II.
CD40L binds to the CD40 that is present on the surface of monocytes, macrophages, and also neutrophils.
Evidences support a central role in the interaction between ligand CD40 (CD40L) and CD40 (its membrane receptor) in the pathogenesis of atherosclerosis (Lutgens and Daemen, 2002; Andre et al.
It has been sug- gested that OPG exists in both membrane-bound and soluble forms and that its expression is up-regulated by CD40 stimulation.